Related Experiment Video
Updated: May 6, 2026
Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
Published on: November 18, 2022
[Anti-apoptotic effect of Astragalus Polysaccharide on myeloid cells]
1Institute of Hematology, Jinan University, Guangzhou 510632, Guangdong Province, China; Department of Hematology, Nanfang Hospital, Southern Medical Uniersity, Guangzhou 510515, Guangdong Province, China.
Abstract:
This study was aimed to assess the effect of Astragalus Polysaccharide (ASPS) on in-vitro hematopoiesis. CFU-GM assays were used to determine the effect of ASPS and thrombopoietin (TPO) on granulocytic-monocyte progenitor cells. The CFU assays were also used to investigate the effect of ASPS on the proliferation of HL-60 cells.HL-60 cells were cultured with serum-free RPMI 1640 medium and treated with or without of different concentrations of ASPS. After 72 h incubation, the number of cells were counted.In addition, the caspase-3 and JC-1 expression was determined by flow cytometry with Annexin V/PI double staining. The results showed that ASPS (100, 200 µg/ml) and TPO (100 ng/ml) significantly promoted CFU-GM formation in vitro. Various concentrations of ASPS and TPO also promoted the colony formation of HL-60 cells, the largest effect of ASPS was observed at a concentration of 100 µg/ml. There were no synergistic effects between TPO and ASPS on cellular proliferation. The results also showed that ASPS significantly protected HL-60 cells from apoptosis in condition of serum-free medium culture, suppressed caspase 3 activation, and reduced the cell apoptosis. It is concluded that ASPS can significantly promote the formation of bone marrow CFU-GM and the proliferation of HL-60 cells, the optimal concentration of ASPS is at 100 µg/ml. In the absence of serum inducing apoptosis, ASPS also significantly reduced the apoptosis of HL-60 cells via suppressing the activation of caspase-3.
Insights
Astragalus Polysaccharide (ASPS) promotes in-vitro hematopoiesis by enhancing granulocytic-monocyte progenitor cell formation and HL-60 cell proliferation. ASPS also protects HL-60 cells from apoptosis by suppressing caspase-3 activation.
Area of Science:
- Hematology
- Cell Biology
- Pharmacology
Context:
- In-vitro hematopoiesis research investigates factors influencing blood cell development.
- Thrombopoietin (TPO) is a key regulator of megakaryopoiesis and platelet production.
- Astragalus Polysaccharide (ASPS) is a natural compound with potential immunomodulatory and hematopoietic effects.
Purpose:
- To evaluate the impact of Astragalus Polysaccharide (ASPS) on in-vitro hematopoiesis.
- To determine the effects of ASPS on granulocytic-monocyte progenitor cells (CFU-GM) and HL-60 cell proliferation.
- To assess ASPS's role in regulating apoptosis in HL-60 cells.
Summary:
- ASPS, at concentrations of 100 and 200 µg/ml, significantly promoted CFU-GM formation in vitro, similar to thrombopoietin (TPO).
- ASPS enhanced the proliferation of HL-60 cells, with optimal effects observed at 100 µg/ml, but showed no synergistic effects with TPO.
- ASPS demonstrated significant anti-apoptotic effects on HL-60 cells in serum-free conditions by suppressing caspase-3 activation.
Impact:
- ASPS promotes bone marrow CFU-GM formation and HL-60 cell proliferation, indicating its potential as a hematopoietic stimulant.
- The optimal concentration for ASPS's hematopoietic effects is identified as 100 µg/ml.
- ASPS exhibits cytoprotective properties by reducing apoptosis, suggesting therapeutic applications in conditions involving cell death.
